European Commission approves oral granule formulation of Gilead Viread
Viread is indicated for HIV-1 infected children between two to six years of age and for HIV-1 infected children more than six years for whom solid dosage is
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The data has also reported positive clinical response activity in classical Hodgkin Lymphoma (HL) patients, who could be the target population for future studies. Sponsored by the Fondazione